Moderna to Host Conference Call on COVID-19 Variants Announcement on Monday, Jan. 25
Moderna, Inc. (Nasdaq: MRNA) announced a conference call on January 25 at 4:30 PM ET to discuss in vitro neutralization studies of its COVID-19 vaccine against emerging SARS-CoV-2 strains. The findings indicate that the vaccine retains neutralizing activity, a critical factor in ongoing pandemic response efforts. The call will also be accessible via a webcast. Over the past decade, Moderna has evolved significantly, demonstrating its mRNA technology's potential with multiple vaccines and therapies in development, enhancing its position in the biotechnology field.
- The COVID-19 vaccine retains neutralizing activity against emerging SARS-CoV-2 strains.
- Moderna has a diverse pipeline with 24 development programs across various therapeutic areas.
- The company has been recognized as a top biopharmaceutical employer for the past six years.
- None.
Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it will hold a conference call today, Monday, January 25 at 4:30 pm ET on the Company’s announcement that results from in vitro neutralization studies of sera from individuals vaccinated with Moderna COVID-19 Vaccine showing activity against emerging strains of SARS-CoV-2.
To access the live conference call, please dial 866-922-5184 (domestic) or 409-937-8950 (international) and refer to conference ID 6346618. A webcast of the call will also be available under “Events and Presentations” in the Investors section of the Moderna website at investors.modernatx.com. The archived webcast will be available on Moderna’s website approximately two hours after the conference call and will be available for one year following the call.
About Moderna
In 10 years since its inception, Moderna has transformed from a science research-stage company advancing programs in the promising-but-still-unproven field of messenger RNA (mRNA), to an enterprise with its first medicine having treated millions of people, a diverse clinical portfolio of vaccines and therapeutics across six modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for both clinical and commercial production at scale and at unprecedented speed. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing. Most recently, Moderna’s capabilities have come together to allow the authorized use of one of the earliest and most-effective vaccines against the COVID-19 pandemic.
Moderna’s mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases. Today, 24 development programs are underway across these therapeutic areas, with 13 programs having entered the clinic. Moderna has been named a top biopharmaceutical employer by Science for the past six years. To learn more, visit www.modernatx.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210125005697/en/
FAQ
What is Moderna's primary focus in biotechnology?
When is the Moderna conference call scheduled?
What was the key finding of Moderna's recent studies?
How many development programs does Moderna currently have?
